[
    [
        {
            "time": "2023-04-21",
            "original_text": "新光药业拟10派4.5元股息率3.02%",
            "features": {
                "keywords": [
                    "新光药业",
                    "股息率",
                    "分红"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "新光药业拟10派4.5元股息率3.02%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "连续3日净买入恒瑞医药获沪股通净买入3.35亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "沪股通",
                    "净买入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "连续3日净买入恒瑞医药获沪股通净买入3.35亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "北上资金连续第5日净买入，成交活跃股名单奉上",
            "features": {
                "keywords": [
                    "北上资金",
                    "净买入",
                    "成交活跃"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金连续第5日净买入，成交活跃股名单奉上",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "连续3日净买入药明康德获沪股通净买入9.92亿元",
            "features": {
                "keywords": [
                    "药明康德",
                    "沪股通",
                    "净买入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "连续3日净买入药明康德获沪股通净买入9.92亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "进入韩国市场！恒瑞医药许可CG公司在韩开发和销售PD-1单克隆抗体",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "韩国市场",
                    "PD-1",
                    "单克隆抗体"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "进入韩国市场！恒瑞医药许可CG公司在韩开发和销售PD-1单克隆抗体",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "融资成本改善，疫情防控债存预期差",
            "features": {
                "keywords": [
                    "融资成本",
                    "疫情防控债",
                    "预期差"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "债券"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "融资成本改善，疫情防控债存预期差",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "A股突现“奇观”，沪深300暴跌中证1000同步暴涨，量化基金表示很受伤",
            "features": {
                "keywords": [
                    "沪深300",
                    "中证1000",
                    "量化基金"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "指数"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股突现“奇观”，沪深300暴跌中证1000同步暴涨，量化基金表示很受伤",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "把握一季报和医药新基建两条投资主线——兼论当前时点为什么我们重点看好疫苗行业",
            "features": {
                "keywords": [
                    "一季报",
                    "医药新基建",
                    "疫苗行业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "把握一季报和医药新基建两条投资主线——兼论当前时点为什么我们重点看好疫苗行业",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "医药板块强势领涨狂欢还能持续多久？医药基金霸屏收益榜",
            "features": {
                "keywords": [
                    "医药板块",
                    "领涨",
                    "收益榜"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药板块强势领涨狂欢还能持续多久？医药基金霸屏收益榜",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "中国第2款CDK4/6抑制剂，今年有望获批！",
            "features": {
                "keywords": [
                    "CDK4/6抑制剂",
                    "获批",
                    "医药创新"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中国第2款CDK4/6抑制剂，今年有望获批！",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]